Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the β deletion variant

Neoplasia

Volumn 10, Issue 10, 2008, Pages 1131-1137

  Lincz, Lisa F ^a,b,c   Mudge, Lisa Maree ^a,c   Scorgie, Fiona E ^a,c   Sakoff, Jennette A ^a,b,c   Hamilton, Christopher S ^a,b,c   Seldon, Michael ^a,c,d  

^a CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d HUNTER NEW ENGLAND HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CANCER CELL CULTURE; CHROMOSOME SIZE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBUNIT; GENE DELETION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; TELOMERE;

EID: 54249156408     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08644     Document Type: Article

References (54)

1. Greider CW and Blackburn EH (1985). Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43, 405-413.
2. Wright WE and Shay JW (1992). The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 27, 383-389.
3. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, and Weinberg RA (1999). Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5, 1164-1170.
4. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, and Weinberg RA (1999). Creation of human tumour cells with defined genetic elements. Nature 400, 464-468.
5. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, and Shay JW (1994). Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015.
6. Glaessl A, Bosserhoff AK, Buettner R, Hohenleutner U, Landthaler M, and Stolz W (1999). Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas. Arch Dermatol Res 291, 81-87.
7. Miracco C, Pacenti L, Santopietro R, Laurini L, Biagioli M, and Luzi P (2000). Evaluation of telomerase activity in cutaneous melanocytic proliferations. Hum Pathol 31, 1018-1021.
8. Kelland L (2007). Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin Cancer Res 13, 4960-4963.
9. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, et al. (1995). The RNA component of human telomerase. Science 269, 1236-1241.
10. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar AG, Lichtsteiner S, Kim NW, Trager JB, et al. (1997). Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 17, 498-502.
11. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Ide T, and Ishikawa F (1998). Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 18, 65-68.
12. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, and Cech TR (1997). Telomerase catalytic subunit homologs from fission yeast and human. Science 277, 955-959.
13. Ulaner GA, Hu JF, Vu TH, Giudice LC, and Hoffman AR (1998). Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 58, 4168-4172.
14. Modrek B and Lee C (2002). A genomic view of alternative splicing. Nat Genet 30, 13-19.
15. Saeboe-Larssen S, Fossberg E, and Gaudernack G (2006). Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues. BMC Mol Biol 7, 26.
16. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR, and Jefferson RA (1997). Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 6, 2011-2019.
17. Hisatomi H, Ohyashiki K, Ohyashiki JH, Nagao K, Kanamaru T, Hirata H, Hibi N, and Tsukada Y (2003). Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene. Neoplasia 5, 193-197.
18. Ulaner GA, Hu JF, Vu TH, Oruganti H, Giudice LC, and Hoffman AR (2000). Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Int J Cancer 85, 330-335.
19. Yi X, Shay JW, and Wright WE (2001). Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res 29, 4818-4825.
20. Yi X, White DM, Aisner DL, Baur JA, Wright WE, and Shay JW (2000). An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia 2, 433-440.
21. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, and Reddel RR (2000). The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2, 426-432.
22. Villa R, Porta CD, Folini M, Daidone MG, and Zaffaroni N (2001). Possible regulation of telomerase activity by transcription and alternative splicing of telomerase reverse transcriptase in human melanoma. J Invest Dermatol 116, 867-873.
23. Barclay JY, Morris AG, and Nwokolo CU (2005). HTERT mRNA partially regulates telomerase activity in gastric adenocarcinoma and adjacent normal gastric mucosa. Dig Dis Sci 50, 1299-1303.
24. Shimojima M, Komine F, Hisatomi H, Shimizu T, Moriyama M, and Arakawa Y (2004). Detection of telomerase activity, telomerase RNA component, and telomerase reverse transcriptase in human hepatocellular carcinoma. Hepatol Res 29, 31-38.
25. Kotoula V, Hytiroglou P, Pyrpasopoulou A, Saxena R, Thung SN, and Papadimitriou CS (2002). Expression of human telomerase reverse transcriptase in regenerative and precancerous lesions of cirrhotic livers. Liver 22, 57-69.
26. Sun PM, Wei LH, Luo MY, Liu G, Wang JL, Mustea A, Konsgen D, Lichtenegger W, and Sehouli J (2007). The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer. Eur J Obstet Gynecol Reprod Biol 130, 249-257.
27. Satra M, Tsougos I, Papanikolaou V, Theodorou K, Kappas C, and Tsezou A (2006). Correlation between radiation-induced telomerase activity and human telomerase reverse transcriptase mRNA expression in HeLa cells. Int J Radiat Biol 82, 401-409.
28. Barclay JY, Morris A, and Nwokolo CU (2005). Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 17, 221-227.
29. Liu WJ, Zhang YW, Zhang ZX, and Ding J (2004). Alternative splicing of human telomerase reverse transcriptase may not be involved in telomerase regulation during all-trans-retinoic acid-induced HL-60 cell differentiation. J Pharmacol Sci 96, 106-114.
30. Zaffaroni N, Villa R, Pastorino U, Cirincione R, Incarbone M, Alloisio M, Curto M, Pilotti S, and Daidone MG (2005). Lack of telomerase activity in lung carcinoids is dependent on human telomerase reverse transcriptase transcription and alternative splicing and is associated with long telomeres. Clin Cancer Res 11, 2832-2839.
31. Yajima T, Yagihashi A, Kameshima H, Furuya D, Kobayashi D, Hirata K, and Watanabe N (2000). Establishment of quantitative reverse transcription- polymerase chain reaction assays for human telomerase-associated genes. Clin Chim Acta 290, 117-127.
32. Bieche I, Nogues C, Paradis V, Olivi M, Bedossa P, Lidereau R, and Vidaud M (2000). Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6, 452-459.
33. Buttitta F, Pellegrini C, Marchetti A, Gadducci A, Cosio S, Felicioni L, Barassi F, Salvatore S, Martella C, Coggi G, et al. (2003). Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. J Clin Oncol 21, 1320-1325.
34. Mavrogiannou E, Strati A, Stathopoulou A, Tsaroucha EG, Kaklamanis L, and Lianidou ES (2007). Real-time RT-PCR quantification of human telomerase reverse transcriptase splice variants in tumor cell lines and non-small cell lung cancer. Clin Chem 53, 53-61.
35. Ohyashiki JH, Hisatomi H, Nagao K, Honda S, Takaku T, Zhang Y, Sashida G, and Ohyashiki K (2005). Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells. Br J Cancer 92, 1942-1947.
36. Sakoff JA, De Waal E, Garg M, Denham J, Scorgie F, Enno A, Lincz LF, and Ackland SP (2002). Telomere length in haemopoietic stem cells can be determined from that of mononuclear blood cells or whole blood. Leuk Lymphoma 43, 2017-2020.
37. Wynn RF, Cross MA, Hatton C, Will AM, Lashford LS, Dexter TM, and Testa NG (1998). Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants [see comments]. Lancet 351, 178-181.
38. Vaziri H, Schachter F, Uchida I, Wei L, Zhu X, Effros R, Cohen D, and Harley CB (1993). Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 52, 661-667.
39. Krams M, Claviez A, Heidorn K, Krupp G, Parwaresch R, Harms D, and Rudolph P (2001). Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas. Am J Pathol 159, 1925-1932.
40. Vandenbroucke II, Vandesompele J, Paepe AD, and Messiaen L (2001). Quantification of splice variants using real-time PCR. Nucleic Acids Res 29, E68.
41. Peirson SN, Butler JN, and Foster RG (2003). Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 31, e73.
42. Cikos S, Bukovska A, and Koppel J (2007). Relative quantification of mRNA: comparison of methods currently used for real-time PCR data analysis. BMC Mol Biol 8, 113.
43. Pirker C, Holzmann K, Spiegl-Kreinecker S, Elbling L, Thallinger C, Pehamberger H, Micksche M, and Berger W (2003). Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. Melanoma Res 13, 483-492.
44. Spiropoulou T, Ferekidou L, Angelopoulou K, Stathopoulou A, Talieri M, and Lianidou ES (2004). Effect of antineoplastic agents on the expression of human telomerase reverse transcriptase beta plus transcript in MCF-7 cells. Clin Biochem 37, 299-304.
45. Folini M, Brambilla C, Villa R, Gandellini P, Vignati S, Paduano F, Daidone MG, and Zaffaroni N (2005). Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur J Cancer 41, 624-634.
46. Brambilla C, Folini M, Gandellini P, Daprai L, Daidone MG, and Zaffaroni N (2004). Oligomer-mediated modulation of hTERT alternative splicing induces telomerase inhibition and cell growth decline in human prostate cancer cells. Cell Mol Life Sci 61, 1764-1774.
47. Li S, Rosenberg JE, Donjacour AA, Botchkina IL, Hom YK, Cunha GR, and Blackburn EH (2004). Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and antitelomerase short-interfering RNA. Cancer Res 64, 4833-4840.
48. Das A, Banik NL, and Ray SK (2008). Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells. J Neurooncol 87, 9-22.
49. Kunisada M, Budiyanto A, Bito T, Nishigori C, and Ueda M (2005). Retinoic acid suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma. Br J Dermatol 152, 435-443.
50. Purev E, Soprano DR, and Soprano KJ (2004). Effect of all-trans retinoic acid on telomerase activity in ovarian cancer cells. J Exp Clin Cancer Res 23, 309-316.
51. Liu L, Berletch JB, Green JG, Pate MS, Andrews LG, and Tollefsbol TO (2004). Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation. Mol Cancer Ther 3, 1003-1009.
52. Bagheri S, Nosrati M, Li S, Fong S, Torabian S, Rangel J, Moore DH, Federman S, Laposa RR, Baehner FL, et al. (2006). Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci USA 103, 11306-11311.
53. Stamm S (2008). Regulation of alternative splicing by reversible protein phosphorylation. J Biol Chem 283, 1223-1227.
54. Carraro G, Albertin G, Forneris M, and Nussdorfer GG (2005). Similar sequence-free amplification of human glyceraldehyde-3-phosphate dehydrogenase for real time RT-PCR applications. Mol Cell Probes 19, 181-186.